DNMT3A and acute myeloid leukemia: Although the prognostic implications of residual mutations in AML patients post‐induction in genes other than DNMT3A, ASXL1, and TET2 have previously been demonstrated,[3] there have been relatively few studies that have examined the significance of NGS‐defined residual disease in the pre‐stem cell transplant setting.